Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 2062661-53-2
2. Imr-687
3. Tovinontrine [usan]
4. Ck1598
5. Af68722
6. W248y1akor
7. Imr687
8. Ck-1598
9. Af-68722
10. 6-((3s,4s)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-3-tetrahydropyran-4-yl-7himidazo(1,5-a)pyrazin-8-one
11. Imidazo(1,5-a)pyrazin-8(7h)-one, 6-((3s,4s)-4-methyl-1-(2-pyrimidinylmethyl)-3-pyrrolidinyl)-3-(tetrahydro-2h-pyran-4-yl)-
12. Tovinontrine [inn]
13. Unii-w248y1akor
14. Tovinontrine [who-dd]
15. Chembl4297290
16. Schembl20358493
17. Bdbm426313
18. Ex-a5357
19. Us10513524, Compound (p3
20. Who 11327
21. Hy-109193
22. Cs-0119133
23. 6-((3s,4s)-4-methyl-1-(2-pyrimidinylmethyl)-3-pyrrolidinyl)-3-(tetrahydro-2h-pyran-4-yl)imidazo(1,5-a)pyrazin-8(7h)-one
24. 6-[(3s,4s)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-(oxan-4-yl)-7h-imidazo[1,5-a]pyrazin-8-one
| Molecular Weight | 394.5 g/mol |
|---|---|
| Molecular Formula | C21H26N6O2 |
| XLogP3 | 0.4 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 4 |
| Exact Mass | 394.21172409 g/mol |
| Monoisotopic Mass | 394.21172409 g/mol |
| Topological Polar Surface Area | 85.2 Ų |
| Heavy Atom Count | 29 |
| Formal Charge | 0 |
| Complexity | 631 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Tovinontrine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Tovinontrine, including repackagers and relabelers. The FDA regulates Tovinontrine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Tovinontrine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Tovinontrine supplier is an individual or a company that provides Tovinontrine active pharmaceutical ingredient (API) or Tovinontrine finished formulations upon request. The Tovinontrine suppliers may include Tovinontrine API manufacturers, exporters, distributors and traders.
Tovinontrine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Tovinontrine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Tovinontrine GMP manufacturer or Tovinontrine GMP API supplier for your needs.
A Tovinontrine CoA (Certificate of Analysis) is a formal document that attests to Tovinontrine's compliance with Tovinontrine specifications and serves as a tool for batch-level quality control.
Tovinontrine CoA mostly includes findings from lab analyses of a specific batch. For each Tovinontrine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Tovinontrine may be tested according to a variety of international standards, such as European Pharmacopoeia (Tovinontrine EP), Tovinontrine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Tovinontrine USP).
LOOKING FOR A SUPPLIER?
